IP Verse

Recombinant Gallid Herpesvirus 3 (Mdv Serotype 2) Vectors Expressing Antigens Of Avian Pathogens And Uses Thereof

Patent No. EP2785374 (titled "Recombinant Gallid Herpesvirus 3 (Mdv Serotype 2) Vectors Expressing Antigens Of Avian Pathogens And Uses Thereof") was filed by Boehringer Ingelheim on Nov 29, 2012. The application was issued on Aug 17, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
INTERVETSep 30, 2019INTERVET

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2785374

BOEHRINGER INGELHEIM
Application Number
EP12805843A
Filing Date
Nov 29, 2012
Status
Patent Maintained As Amended
Jul 15, 2022
Publication Date
Aug 17, 2022
External Links
Slate, Register , Google Patents